Zare M, et al. Aberrant miRNA promoter methylation and EMT-involving miRNAs in breast cancer metastasis: diagnosis and therapeutic implications. J Cell Physiol. 2018;233(5):3729–44.
Article
CAS
PubMed
Google Scholar
Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Article
Google Scholar
Dafni U, Tsourti Z, Alatsathianos I. Breast cancer statistics in the European Union: incidence and survival across European countries. Breast Care. 2019;14(6):344–53.
Article
PubMed
PubMed Central
Google Scholar
Cardoso F, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–220.
Article
CAS
PubMed
Google Scholar
Baradaran B, Hajiasgharzadeh K. Breast cancer among young women in Iran. Int J Women’s Health Reprod Sci. 2019;7(2):140.
Article
Google Scholar
Fuentes P, et al. ITGB3-mediated uptake of small extracellular vesicles facilitates intercellular communication in breast cancer cells. Nat Commun. 2020;11(1):1–15.
Article
CAS
Google Scholar
Ng CK, Pemberton HN, Reis-Filho JS. Breast cancer intratumor genetic heterogeneity: causes and implications. Expert Rev Anticancer Ther. 2012;12(8):1021–32.
Article
CAS
PubMed
Google Scholar
Delgir S, et al. The pathways related to glutamine metabolism, glutamine inhibitors and their implication for improving the efficiency of chemotherapy in triple-negative breast cancer. Mutat Res Rev Mutat Res. 2021;787:108366.
Article
CAS
Google Scholar
El Ansari R, et al. Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations. Histopathology. 2018;72(2):183–90.
Article
PubMed
Google Scholar
Kim S, et al. Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer. Endocr Relat Cancer. 2013;20(3):339–48.
Article
CAS
PubMed
Google Scholar
Lampa M, et al. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition. PLoS ONE. 2017;12(9):e0185092.
Article
PubMed
PubMed Central
CAS
Google Scholar
Bacci M, et al. miR-155 drives metabolic reprogramming of ER+ breast cancer cells following long-term estrogen deprivation and predicts clinical response to aromatase inhibitors. Can Res. 2016;76(6):1615–26.
Article
CAS
Google Scholar
Ilkhani K, et al. The engaged role of tumor microenvironment in cancer metabolism: focusing on cancer-associated fibroblast and exosome mediators. Anti Cancer Agents Med Chem. 2020;21:254–66.
Article
CAS
Google Scholar
Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Investig. 2013;123(9):3678–84.
Article
CAS
PubMed
PubMed Central
Google Scholar
Korangath P, et al. Targeting glutamine metabolism in breast cancer with aminooxyacetate. Clin Cancer Res. 2015;21(14):3263–73.
Article
CAS
PubMed
PubMed Central
Google Scholar
Marshall A, et al. ASCT2 regulates glutamine uptake and cell growth in endometrial carcinoma. Oncogenesis. 2017;6(7):e367–e367.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gao P, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458(7239):762–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pahlavan Y, et al. Prominent roles of microRNA-142 in cancer. Pathol Res Pract. 2020;216:153220.
Article
CAS
PubMed
Google Scholar
Safi A, et al. miRNAs modulate the dichotomy of cisplatin resistance or sensitivity in breast cancer: an update of therapeutic implications. Anti Cancer Agents Med Chem. 2020;21:1069–81.
Article
CAS
Google Scholar
Nejati K, Alivand M, Arabzadeh A. MicroRNA-22 in female malignancies: focusing on breast, cervical, and ovarian cancers. Pathol Res Pract. 2021;21:153452.
Article
CAS
Google Scholar
Soheilifar MH, et al. Concomitant overexpression of mir-182-5p and mir-182-3p raises the possibility of IL-17–producing Treg formation in breast cancer by targeting CD3d, ITK, FOXO1, and NFATs: A meta-analysis and experimental study. Cancer Sci. 2021;112(2):589.
Article
CAS
PubMed
Google Scholar
Khoshmirsafa M, et al. Elevated expression of miR-21 and miR-155 in peripheral blood mononuclear cells as potential biomarkers for lupus nephritis. Int J Rheum Dis. 2019;22(3):458–67.
Article
CAS
PubMed
Google Scholar
Zhang K, et al. LncRNA FLVCR1-AS1 acts as miR-513c sponge to modulate cancer cell proliferation, migration, and invasion in hepatocellular carcinoma. J Cell Biochem. 2018;119(7):6045–56.
Article
CAS
PubMed
Google Scholar
Wang B-D, et al. Identification and functional validation of reciprocal microRNA–mRNA pairings in African American prostate cancer disparities. Clin Cancer Res. 2015;21(21):4970–84.
Article
CAS
PubMed
PubMed Central
Google Scholar
Xu J, Sun T, Hu X. microRNA-513c suppresses the proliferation of human glioblastoma cells by repressing low-density lipoprotein receptor-related protein 6. Mol Med Rep. 2015;12(3):4403–9.
Article
CAS
PubMed
Google Scholar
Xia H-L, et al. MiR-513c suppresses neuroblastoma cell migration, invasion, and proliferation through direct targeting glutaminase (GLS). Cancer Biomark. 2017;20(4):589–96.
Article
CAS
PubMed
Google Scholar
Hsieh T-H, et al. HDAC inhibitors target HDAC5, upregulate microRNA-125a-5p, and induce apoptosis in breast cancer cells. Mol Ther. 2015;23(4):656–66.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang H, et al. MicroRNA expression signatures in Barrett’s esophagus and esophageal adenocarcinoma. Clin Cancer Res. 2009;15(18):5744–52.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jia M, et al. Silencing of ABCG2 by microRNA-3163 inhibits multidrug resistance in retinoblastoma cancer stem cells. J Korean Med Sci. 2016;31(6):836–42.
Article
CAS
PubMed
PubMed Central
Google Scholar
Su L, et al. Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163. Tumor Biol. 2016;37(3):3925–31.
Article
CAS
Google Scholar
Subramaniam S, et al. Emergence of MicroRNAs as key players in cancer cell metabolism. Clin Chem. 2019;65(9):1090–101.
Article
CAS
PubMed
Google Scholar
Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134(5):703–7.
Article
CAS
PubMed
Google Scholar
Ilkhani K, et al. Clinical and in silico outcomes of miR-130a-5p and miR-615-3p expression in tumor compared with non-tumor adjacent tissues of patients with BC. Anti Cancer Agents Med Chem. 2021;21:927–35.
Article
CAS
Google Scholar
Katt WP, Cerione RA. Glutaminase regulation in cancer cells: a druggable chain of events. Drug Discov Today. 2014;19(4):450–7.
Article
CAS
PubMed
Google Scholar
Masisi BK, et al. The role of glutaminase in cancer. Histopathology. 2020;76(4):498–508.
Article
PubMed
Google Scholar
Rahmati Y, Alivand M, Mollanoori H. MiR-330-3p and miR-485-5p as biomarkers for glioblastoma: an integrated bioinformatics and experimental study. Comput Biol Chem. 2021;92:107458.
Article
CAS
PubMed
Google Scholar
Xiong YZ, Wang J, Cao X. MiR-513c suppresses neuroblastoma cell migration, invasion, and proliferation through direct targeting glutaminase (GLS). Cancer Biomark. 2018;23(311):311.
Google Scholar
Zografos E, et al. Prognostic role of microRNAs in breast cancer: a systematic review. Oncotarget. 2019;10(67):7156.
Article
PubMed
PubMed Central
Google Scholar
Ilkhani K, et al. Clinical and in silico outcomes of the expression of miR-130a-5p and miR-615-3p in tumor compared with non-tumor adjacent tissues of patients with BC. Anti Cancer Agents Med Chem (Former Curr Med Chem Anti Cancer Agents). 2021;21(7):927–35.
CAS
Google Scholar
Zhang L-F, Jiang S, Liu M-F. MicroRNA regulation and analytical methods in cancer cell metabolism. Cell Mol Life Sci. 2017;74(16):2929–41.
Article
CAS
PubMed
Google Scholar
Zhan M-N, et al. MicroRNA-494 inhibits breast cancer progression by directly targeting PAK1. Cell Death Dis. 2018;8(1):e2529–e2529.
Article
CAS
Google Scholar
Pedroza-Torres A, et al. microRNAs in tumor cell metabolism: Roles and therapeutic opportunities. Front Oncol. 2019;9:1404.
Article
PubMed
PubMed Central
Google Scholar
Lin D, et al. Metabolic heterogeneity signature of primary treatment-naive prostate cancer. Oncotarget. 2017;8(16):25928.
Article
PubMed
PubMed Central
Google Scholar
Mittal S, et al. Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis. Mol Cancer. 2009;8(1):128.
Article
PubMed
PubMed Central
CAS
Google Scholar
Jia Y, et al. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer. Cell Signal. 2018;42:165–75.
Article
CAS
PubMed
Google Scholar
Mirzoeva OK, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009;69(2):565–72.
Article
CAS
PubMed
PubMed Central
Google Scholar
Thangavelu K, et al. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf–Mek–Erk signaling in cancer cell metabolism. Proc Natl Acad Sci. 2012;109(20):7705–10.
Article
CAS
PubMed
PubMed Central
Google Scholar
Souzaki M, et al. Hedgehog signaling pathway mediates the progression of non-invasive breast cancer to invasive breast cancer. Cancer Sci. 2011;102(2):373–81.
Article
CAS
PubMed
Google Scholar
Li J, et al. Regulation of hepatic stellate cell proliferation and activation by glutamine metabolism. PLoS ONE. 2017;12(8):e0182679.
Article
PubMed
PubMed Central
CAS
Google Scholar
Mo Y, et al. The role of Wnt signaling pathway in tumor metabolic reprogramming. J Cancer. 2019;10(16):3789.
Article
CAS
PubMed
PubMed Central
Google Scholar
Koval A, Katanaev VL. Dramatic dysbalancing of the Wnt pathway in breast cancers. Sci Rep. 2018;8(1):1–10.
Article
CAS
Google Scholar